CWM
MRNA icon

Congress Wealth Management’s Moderna MRNA Stock Holding History

Congress Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,384
Closed -$521K – 860
2024
Q2 		$521K Sell
4,384
-101
-2% -$12.8K 0.01% 531
2024
Q1 		$479K Sell
4,485
-1,657
-27% -$167K 0.01% 454
2023
Q4 		$611K Buy
6,142
+1,401
+30% +$118K 0.01% 441
2023
Q3 		$490K Sell
4,741
-803
-14% -$89.6K 0.01% 463
2023
Q2 		$674K Sell
5,544
-11
-0.2% -$1.47K 0.02% 379
2023
Q1 		$853K Buy
5,555
+247
+5% +$40.7K 0.02% 360
2022
Q4 		$959K Buy
5,308
+260
+5% +$42.5K 0.02% 340
2022
Q3 		$596K Hold
5,048
– – 0.02% 385
2022
Q2 		$722K Sell
5,048
-10
-0.2% -$1.43K 0.02% 368
2022
Q1 		$878K Sell
5,058
-1,582
-24% -$266K 0.02% 370
2021
Q4 		$1.69M Buy
+6,640
New +$1.94M 0.03% 321

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Congress Wealth Management's MRNA Position: Q3 2024 in Review

Congress Wealth Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 4,384 shares — an estimated $521K sold.

Congress Wealth Management first reported a position in MRNA in Q4 2021 and held it in 11 quarters. The position peaked at $1.69M in Q4 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Congress Wealth Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Congress Wealth Management sold 4,384 Moderna shares in Q3 2024, an estimated $521K.
  • Congress Wealth Management first reported a position in Moderna in Q4 2021 and held it in 11 quarters.
  • Congress Wealth Management's Moderna position peaked at $1.69M in Q4 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Congress Wealth Management's 13F filing for Q3 2024, filed 12 Nov 2024.